Loading...
XKRX199800
Market cap406mUSD
Aug 16, Last price  
75,300.00KRW
Name

ToolGen Inc

Chart & Performance

D1W1MN
XKRX:199800 chart
P/E
—
P/S
540.26
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.50%
Rev. gr., 5y
-0.94%
Revenues
1.10b
+48.41%
1,501,978,8202,116,891,1401,540,265,3803,338,322,4501,156,831,6301,125,062,520713,092,8801,597,275,450743,463,6101,103,409,420
Net income
-42.34b
L+132.93%
147,611,300-5,147,179,190-3,016,631,450-4,342,908,080-8,056,827,180-16,277,597,380-14,733,351,780-20,730,863,000-18,177,221,000-42,340,173,000
CFO
-14.91b
L-0.53%
324,280,670-292,680,200-3,356,198,850-1,785,240,650-6,290,853,680-9,974,249,260-10,070,210,380-14,827,687,150-14,986,540,420-14,907,423,230

Profile

ToolGen Inc is a biotechnology company, which focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified, gRNA/Cas9, and recombinant Cas9 protein, which offers ready-to-use reagents for genome engineering experiments. The company also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services.
URL
http://www.toolgen.com/
IPO date
Jun 25, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,103,409
48.41%
743,464
-53.45%
1,597,275
123.99%
Cost of revenue
11,977,208
12,717,657
14,442,521
Unusual Expense (Income)
NOPBT
(10,873,799)
(11,974,193)
(12,845,246)
NOPBT Margin
Operating Taxes
67
38,385
Tax Rate
NOPAT
(10,873,799)
(11,974,260)
(12,883,631)
Net income
(42,340,173)
132.93%
(18,177,221)
-12.32%
(20,730,863)
40.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,006,601
962,043
70,715,594
BB yield
-0.22%
-11.37%
Debt
Debt current
21,752
19,095
72,981
Long-term debt
60,514,899
20,866
112,943
Deferred revenue
Other long-term liabilities
1,175,683
1,102,050
1,004,833
Net debt
24,578,991
(17,324,649)
(13,387,654)
Cash flow
Cash from operating activities
(14,907,423)
(14,986,540)
(14,827,687)
CAPEX
(6,684,456)
(5,380,948)
(617,703)
Cash from investing activities
(716,215)
17,609,013
(57,977,677)
Cash from financing activities
33,964,301
887,512
70,604,399
FCF
(13,896,140)
(17,195,906)
(14,236,222)
Balance
Cash
64,649,772
52,696,587
72,250,765
Long term investments
(28,692,112)
(35,331,977)
(58,677,187)
Excess cash
35,902,490
17,327,437
13,493,714
Stockholders' equity
(131,838,479)
(89,351,580)
(71,003,563)
Invested Capital
223,539,864
160,942,656
156,764,741
ROIC
ROCE
EV
Common stock shares outstanding
7,911
7,855
6,863
Price
54,900.00
-39.40%
90,600.00
-18.38%
Market cap
431,255,750
-30.64%
621,762,885
-14.60%
EV
413,931,102
608,375,231
EBITDA
(9,332,143)
(10,898,991)
(11,970,580)
EV/EBITDA
Interest
428,245
28,375
29,252
Interest/NOPBT